Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer

被引：3

作者：

Teitelbaum, Ursina R. ^{[1
]}

Haller, Daniel G. ^{[1
]}

机构：

[1] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 05期

关键词：

CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; THERAPY;

D O I：

10.1038/nrclinonc.2009.46

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. this paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.

引用

页码：250 / 251

页数：3

共 50 条

[1] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
Ursina R. Teitelbaum
Daniel G. Haller
Nature Reviews Clinical Oncology, 2009, 6 : 250 - 251
[2] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
Grothey, Axel
NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01): : 10 - 11
[3] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
Axel Grothey
Nature Clinical Practice Oncology, 2009, 6 : 10 - 11
[4] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy
S Clarke
E Díaz-Rubio
W Scheithauer
A Figer
R Wong
S Koski
K Rittweger
F Gilberg
L Saltz
British Journal of Cancer, 2011, 105 : 58 - 64
[5] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
Cassidy, J.
Clarke, S.
Diaz-Rubio, E.
Scheithauer, W.
Figer, A.
Wong, R.
Koski, S.
Rittweger, K.
Gilberg, F.
Saltz, L.
BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 58 - 64
[6] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
Rothenberg, M. L.
Cox, J. V.
Butts, C.
Navarro, M.
Bang, Y. -J.
Goel, R.
Gollins, S.
Siu, L. L.
Laguerre, S.
Cunningham, D.
ANNALS OF ONCOLOGY, 2008, 19 (10) : 1720 - 1726
[7] Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
Shi, Sha
Lu, Kemei
Gao, Hui
Sun, Huidong
Li, Senlin
AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (09): : 1971 - 1977
[8] FOLFOX-4 Regimen as a First-line Therapy for Cuban Patients with Metastatic Colorectal Cancer
Lami, Leonardo
Areces, Fernando
Lence, Juan J.
Arbesu, Maria A.
MEDICC REVIEW, 2009, 11 (03) : 34 - 38
[9] A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
Darba, J.
Restovic, G.
Ramirez de Arellano, A.
VALUE IN HEALTH, 2008, 11 (06) : A467 - A467
[10] Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
Jeon, Eun Kyoung
Hong, Sook Hee
Kim, Tae Hee
Jung, Seung Eun
Park, Ji Chan
Won, Hye-Sung
Ko, Yoon-Ho
Rho, Sang Young
Hong, Young Seon
CANCER RESEARCH AND TREATMENT, 2011, 43 (03): : 148 - 153

← 1 2 3 4 5 →